SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending intensely after a strong earnings report highlighted by surging AI chip revenue, a new OpenAI partnership, and significantly raised future guidance alongside a substantial share repurchase program. This has ignited strong bullish sentiment on its foundational role in the accelerating AI infrastructure, while some community members debate valuation and anticipate profit-taking.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is experiencing a surge following reports of early talks with OpenAI for a potential partnership to integrate advertising into ChatGPT, which the community views as a significant new revenue opportunity in the AI space. This development, combined with a massive $148 million insider share purchase by the CEO, is sparking widespread discussion about a potential short squeeze and a turnaround for the recently oversold stock.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors digest its Q4 earnings and reiterated 2026 guidance, with community debate centering on conservative future projections and management's communication regarding the TDAPA transition and ongoing high short interest. Many view the newly authorized $75 million share repurchase program, alongside upcoming Rezzayo Phase 3 data, as key catalysts for a stock perceived by some to be significantly undervalued.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending following strong Q4 2025 earnings that showcased significant revenue growth and positive adjusted EBITDA, alongside optimistic 2026 guidance. The community is actively discussing the company's superior silicon anode battery technology as crucial for the rapidly expanding defense and drone markets, buoyed by progress in US-based manufacturing.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as the community eagerly anticipates the long-awaited Phase 3 REGAL trial results for its AML immunotherapy, with many speculating a big pharma buyout is imminent due to unprecedented patient survival rates and unusual executive silence. Investors are betting on a "near-cure" and significant upside, despite persistent short interest leading to a heated debate between bulls and bears.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is seeing significant interest following robust Q4 earnings, strong FY26 revenue guidance, and new defense contracts for missile propulsion and advanced multi-domain swarming autonomy, fueling community discussions about its potential as a leading defense AI player amidst notable short interest.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is trending following its Q4 earnings, where initial confusion over EPS figures has been clarified to an inline beat, accompanied by strong revenue growth and record customer assets. While bulls highlight global expansion and new AI tools, the community remains divided over concerns regarding aggressive growth-related spending, ongoing share dilution, and the stock's persistent underperformance against a backdrop of positive operational metrics.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma (HELP) is trending as the community reacts to a significant stock sell-off despite positive topline Phase 2 results for its generalized anxiety disorder treatment, HLP004, with many investors debating if the market is overreacting to the strong data.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com's recent quarterly earnings, which showed missed revenue and a net loss amid aggressive competition and investments in new ventures like food delivery, are fueling investor frustration over its profitability and stock performance, though some highlight its robust cash position and deep undervaluation as a long-term opportunity in the challenging Chinese e-commerce market.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending after reporting significantly missed Q4 revenue and widening losses, leading to widespread community frustration over its multi-billion dollar market cap versus negligible sales. Many are debating if the quantum computing pure-play is an overvalued "science project" or a long-term strategic bet, with some anticipating further drops and others eyeing a short squeeze despite the poor financials.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ADC Therapeutics (NYSE:ADCT) Sees Strong Trading Volume - Here's What Happened

ADC Therapeutics (NYSE:ADCT) Sees Strong Trading Volume - What's Next...

ADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of "Moderate Buy" from Brokerages

ADC Therapeutics SA (NYSE:ADCT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five analysts that are presently covering the firm, MarketBeat reports. One research...

ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026

ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026 ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference...

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, March 2, 2026 LAUSANNE...

ADC Therapeutics to Participate in March Investor Conferences

ADC Therapeutics to Participate in March Investor Conferences ADC Therapeutics to Participate in March Investor Conferences PR Newswire LAUSANNE, Switzerland, Feb. 24, 2026 LAUSANNE, Switzerland...

ADC Therapeutics (NYSE:ADCT) Shares Up 6.7% - Time to Buy?

ADC Therapeutics (NYSE:ADCT) Trading 6.7% Higher - What's Next...

ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement

ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement PR Newswire LAUSANNE, Switzerland, Feb. 23, 2026...

ADC Therapeutics SA (NYSE:ADCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of ADC Therapeutics SA (NYSE:ADCT - Get Free Report) have received an average rating of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat.com reports. One equities...

ADC Therapeutics (NYSE:ADCT) Trading Down 4.5% - Here's What Happened

ADC Therapeutics (NYSE:ADCT) Trading Down 4.5% - Here's Why...

ADC Therapeutics (NYSE:ADCT) Stock Price Down 4.5% - Here's Why

ADC Therapeutics (NYSE:ADCT) Stock Price Down 4.5% - What's Next...

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Current Price	$4.15
Prev Close	$4.24
Open	$4.22
Dividend Yield	0.00%
50-Day Moving Average	$3.82
Beta	1.49
Avg. Volume	772,271.51
PE Ratio	-2.92

52-Week High	$4.80
52-Week Low	$1.05
Market Capitalization	$536.1M
EPS (Annual)	-$1.62
Price to Book	-2.00
Revenue Per Employee	$267,309.43

ADCT
Adc Therapeutics SA

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ADCT News

ADCTAdc Therapeutics SA